“Identifying the cancer stem cell and the evolutionarily conserved genetic programs underlying self-renewal in ERMS will likely lead to new insights into how to destroy these cell types in established malignancies,” explains Dr. Zon.
Rhabdomyosarcoma (RMS) is an aggressive cancer that arises from a primitive skeletal muscle cell called a "rhabdomyoblast". Depending upon on the histology of the cancerous cells, there are several different subtypes of RMS. Embryonal rhabdomyosarcoma (ERMS) is the most common subtype, usually found in children under 15, in the head and neck region and genitourinary tract.
Dr. Zon and colleagues have developed an animal model to identify and test therapeutic targets of human ERMS. The scientists artificially activated the RAS pathways to induce ERMS in a strain of genetically engineered zebrafish. Some transgenic zebrafish developed visible tumors by 10 days of age.
Through their model, Dr. Zon and colleagues were able to identify both an ERMS tumor-cell-of-origin and a novel genetic signature that underlies ERMS progression in zebrafish and human patients. Cancer stem cells make up only a small fraction of the overall number of cells in a tumor. However, they are capable of giving rise to other cancer cells, and thereby drive tumor growth and metastasis. To prevent recurrence and progression, effective long-term therapies must target the self-renewing population of cancer stem cells.
“The zebrafish is ideally suited for use in targeted chemical genetic approaches to specifically inactivate cancer pathways we have identified in our study. Identifying drugs that inactivate these pathways in the ERMS cancer stem cell may have far reaching implications for treatment of patients with this disease.”
Source: Cold Spring Harbor Laboratory
Related stories:
Landmark study unlocks stem cell, DNA secrets to speed therapies
In a groundbreaking study led by an eminent molecular biologist at Florida State University, researchers have discovered that as embryonic stem cells turn into different cell types, there are dramatic corresponding changes to the order in which DNA is replicated and reorganized.
A link between mitochondria and tumor formation in stem cells
Researchers report on a previously unknown relationship between stem cell potency and the metabolic rate of their mitochondria –a cell's energy makers. Stem cells with more active mitochondria also have a greater capacity to differentiate and are more likely to form tumors.
Researcher eliminates viral vector in stem cell reprogramming
Shinya Yamanaka MD, PhD, of Kyoto University and the Gladstone Institute of Cardiovascular Disease (GICD) has taken another step forward in improving the possibilities for the practical application of induced pluripotent stem (iPS) cell technology.
Breast stem cell fate is regulated by 'notch'
A normal developmental protein that sometimes goes awry has been implicated in breast cancer. This discovery indicates the mechanism by which inappropriate expression of the Notch pathway may contribute to breast cancer.
Scientists pinpoint key proteins in blood stem cell replication
A family of cancer-fighting molecules helps blood stem cells in mice decide when and how to divide, say researchers at the Stanford University School of Medicine. Blocking the molecules' function spurs the normally resting cells to begin proliferating strangely - making too much of one kind of cell and not enough of another. Many types of human blood cancers involve a similar disruption in the expression of that same family of molecules.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of
Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
Scientists identify a molecule that coordinates the movement of cells
Even cells commute. To get from their birthplace to their work site, they sequentially attach to and detach from an elaborate track of exceptionally strong proteins known as the extracellular matrix. Now, in research to appear in the October 3 issue of
Cell, scientists at the Howard Hughes Medical Institute and Rockefeller University show that a molecule, called ACF7, helps regulate and power this movement from the inside - findings that could have implications for understanding how cancer cells metastasize.
The role of stem cells in renewing the cornea
A group of researchers in Switzerland has published a study appearing in the Oct 1 advance online edition of the Journal
Nature that shows how the cornea uses stem cells to repair itself.